Compare · BTI vs NAGE
BTI vs NAGE
Side-by-side comparison of British American Tobacco Industries p.l.c. (BTI) and Niagen Bioscience Inc. (NAGE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BTI and NAGE operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- BTI is the larger of the two at $136.23B, about 521.5x NAGE ($261.2M).
- Over the past year, BTI is up 21.3% and NAGE is down 66.2% - BTI leads by 87.5 points.
- NAGE has been more active in the news (11 items in the past 4 weeks vs 2 for BTI).
- BTI has more recent analyst coverage (14 ratings vs 1 for NAGE).
PerformanceBTI+21.27%NAGE-66.20%
2025-07-21+0.00%2026-07-17
- Company
- British American Tobacco Industries p.l.c.
- Niagen Bioscience Inc.
- Price
- $62.83-0.51%
- $3.27-3.96%
- Market cap
- $136.23B
- $261.2M
- 1M return
- +2.39%
- -4.94%
- 1Y return
- +21.27%
- -66.20%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NYSE
- NASDAQ
- IPO
- 1998
- News (4w)
- 2
- 11
- Recent ratings
- 14
- 1
BTI
British American Tobacco Industries p.l.c.
British American Tobacco p.l.c. provides tobacco and nicotine products to consumers worldwide. It offers vapour products, tobacco heating products, and modern oral products; combustible products; and traditional oral products, such as Swedish-style snus and American moist snuff. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.
Latest BTI
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 11-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
Latest NAGE
- Niagen Bioscience Appoints Abhijit Kale, Ph.D., as Senior Director of Global External Research
- Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)
- SEC Form 424B5 filed by Niagen Bioscience Inc.
- SEC Form EFFECT filed by Niagen Bioscience Inc.
- Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026
- SVP, General Counsel Lopez Carlos Luis was granted 2,314 shares, increasing direct ownership by 103% to 4,565 units (SEC Form 4)
- Chief Financial Officer Pamir Ozan was granted 4,255 shares, increasing direct ownership by 58% to 11,627 units (SEC Form 4)
- Chief Executive Officer Fried Robert N was granted 1,106 shares, increasing direct ownership by 0.10% to 1,060,087 units (SEC Form 4)
- Niagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseases
- Niagen Bioscience Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders